LITHIUM CARBONATE INHIBITION OF I-131 RELEASE BY THYR.CARCINOMA

临床内分泌科对本病的治疗进行了随访研究。 分化型甲状腺癌。在这项研究中，患者经常被给予 I-131治疗。碳酸锂抑制甲状腺激素的释放 通过正常的甲状腺。在甲状腺癌项目中，锂 碳酸盐用于分化型甲状腺癌患者 阻断I-131从肿瘤沉积物中的释放。成功地封锁了 I-131的释放延长了I-131在肿瘤中的滞留时间， 从而增加了被肿瘤捕获的每个MC所提供的辐射剂量。 在这项研究中，患者被给予两个1.5mCI示踪剂I-131。连载 肿瘤活动的核医学图像是在治疗后获得的 I-131在肿瘤内滞留的生物T1/2为 计算出来的。最初的研究是基线评估，随后是 第二项研究是在患者服用锂时进行的。目的 这项研究是为了确定锂效应的频率，并 确定辐射剂量是否显著增加 肿瘤是可以实现的。这项研究的初步报告是 出版了。

The Clinical Endocrinology Branch has a follow-up study of the treatment of differentiated thyroid Carcinoma. In this study patients are often given I-131 treatment. Lithium carbonate inhibits the release of thyroid hormone by the normal thyroid gland. In the thyroid carcinoma project, lithium carbonate is given to patients with differentiated thyroid carcinoma to block the release of I-131 from tumor deposits. Successful blockade of the I-131 release prolongs the residence time of the I-131 in the tumor and thus increases the radiation dose delivered per mC trapped by the tumor. In the study patients are given two 1.5 mCi tracer doses of I-131. Serial Nuclear Medicine images of the activity in the tumor are obtained after the doses and the biological T1/2 of I-131 residence in the tumor is calculated. The initial study, a baseline evaluation, is followed by a second study performed when the patient is taking Lithium. The purpose of the study is to determine the frequency of a lithium effect, and to determine whether a significant increase in the radiation dose delivered to the tumor can be achieved. A preliminary report of this study has been published.